
Sign up to save your podcasts
Or


Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.
By Newstalk ZB5
11 ratings
Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.

2 Listeners

50 Listeners

8 Listeners

51 Listeners

22 Listeners

5 Listeners

1 Listeners

19 Listeners

0 Listeners

7 Listeners

1 Listeners

21 Listeners

113 Listeners

0 Listeners

15 Listeners

29 Listeners

0 Listeners

3 Listeners

0 Listeners

0 Listeners

14 Listeners

15 Listeners

5 Listeners

58 Listeners

6 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

13 Listeners

0 Listeners

0 Listeners